

## Certificate of Analysis

### cdk2/cyclin A, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-448, 14-448-K, 14-448M

Parent Lot # 25774U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** C-terminal 6His-tagged human full length cdk2, and N-terminal GST-tagged human full length cyclin A. These are expressed individually by baculovirus in Sf21 insect cells. The cdk2 is purified by Ni<sup>2+</sup>/NTA agarose and then activated using CAK and repurified by Q Sepharose and Ni<sup>2+</sup>/NTA agarose. The cyclin A is purified using glutathione-agarose. They are then complexed *in vitro*. Combined purity 43% by SDS-PAGE and Coomassie blue staining. cdk2 MW = 35kDa and cyclin A MW = 75kDa.

**Specific Activity (Parent lot# 25774U):** 184U/mg, where one unit of cdk2/cyclinA, active activity is defined as 1nmol phosphate incorporated into 0.1mg/ml histone H1 per minute at 30°C with a final ATP concentration of 100µM.

**Formulation:** 1.076mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

**Kinase Assay:** 11–54ng of this lot of enzyme phosphorylated 0.1mg/ml histone H1 in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



**MS Tryptic Fingerprint:** Confirmed product identity as cdk2 with the translated native sequence listed on page three and cyclin A with the translated native sequence listed on page four



## Certificate of Analysis

### Kinase Assay Protocol

#### Stock Solutions:

- 1. 5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- 2. Histone H1:** Use at a final assay concentration of 0.1mg/ml. Prepare a 1mg/ml stock in 20mM MOPS pH7.0 and add 2.5µl of stock per assay point.
- 3. cdk2/cyclin A, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 11–54ng per assay point.
- 4. [ $\gamma$ -<sup>33</sup>P]ATP:** 2.5 x magnesium acetate/[ $\gamma$ -<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [ $\gamma$ -<sup>33</sup>P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

#### Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of **histone H1**.
3. Add **2.5µl (11–54ng) cdk2/cyclin A, active**.
4. Add 5µl of dH<sub>2</sub>O.
5. Add 10µl of diluted [ $\gamma$ -<sup>33</sup>P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

# Certificate of Analysis

## cdk2 Sequence Information

<b><u>Protein</u></b>	human cdk2
<b><u>Tags</u></b>	C-terminal 6His
<b><u>Native sequence</u></b>	M1 of the recombinant protein is equivalent to M1 of human CDK2
<b><u>Accession number</u></b>	EMBL M68520

### ***Recombinant cdk2 amino acid sequence:***

```

1  MENFQKVEKI GEGTYGVVYK ARNKLTGEVW ALKKIRLDTE TEGVPSTAIR EISLLKELNH
61  PNIVKLLDVI HTENKLYLVF EFLHQDLKKF MDASALTGIP LPLIKSYLFQ LLQGLAFCHS
121 HRVLHRDLKP QNLLINTEGA IKLADFLAR AFGVPVRTYT HEVVTWLYRA PEILLGCKYY
181 STAVDIWSLG CIFAEMVTRR ALFPGDSEID QLFRIFRITLG TPDEVVWPGV TSMPDYKPSF
241 PKWARQDFSK VVPLDEDGR SLLSQMLHYD PNKRISAKAA LAHPFFQDVT KVPVHLRLHH
301  HHHH

```

### ***Recombinant cdk2 nucleotide sequence:***

```

1  atggagaact tccaaaaggt ggaaaagatc ggagagggca cgtacggagt tgtgtacaaa
61  gccagaaaca agttgacggg agaggtgggt gcgcttaaga aaatccgcct ggacactgag
121 actgaggggtg tgcccagtac tgccatccga gagatctctc tgcttaagga gcttaacat
181 cctaataattg tcaagctgct ggatgtcatt cacacagaaa ataaactcta cctggttttt
241 gaatttctgc accaagatct caagaaattc atggatgcct ctgctctcac tggcattcct
301 cttcccctca tcaagagcta tctgttccag ctgctccagg gcctagcttt ctgccattct
361 catcgggtcc tccaccgaga ccttaaacct cagaatctgc ttattaacac agagggggcc
421 atcaagctag cagactttgg actagccaga gcttttggag tccctgttcg tacttacacc
481 catgaggtgg tgaccctgtg gtaccgagct cctgaaatcc tcctgggctg caaatattat
541 tccacagctg tggacatctg gagcctgggc tgcaccttg ctgagatggt gactcgccgg
601 gccctattcc ctggagattc tgagattgac cagctcttcc ggatctttcg gactctgggg
661 acccagatg aggtggtgtg gccaggagtt acttctatgc ctgattacaa gccaagtttc
721 cccaagtggg cccggcaaga ttttagtaaa gttgtacctc ccctggatga agatggacgg
781 agcttgttat cgcaaatgct gcactacgac cctaacaagc ggatttcggc caaggcagcc
841 ctggctcacc ctttctcca ggatgtgacc aagccagtac cccatcttcg actccatcac
901 catcaccatc attga

```

# Certificate of Analysis

## cyclin A Sequence Information

<b><u>Protein</u></b>	human cyclin A
<b><u>Tags</u></b>	N-terminal GST
<b><u>Native sequence</u></b>	M231 of the recombinant protein is equivalent to M1 of human cyclin A
<b><u>Accession number</u></b>	EMBL X51688

### ***Recombinant cyclinA amino acid sequence:***

```

1 MSPILGYWKI KGLVQPTRL L LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
61 GDVKLTQ SMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSR IA YSKDFETLKV
121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK
181 KRIEAI PQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LEVLFQGP EF MLGNSAPGPA
241 TREAGSALLA LQQTALQEDQ ENINPEKAAP VQQPRTRAAL AVLKSGNPRG LAQQQRPKTR
301 RVAPLKDLPV NDEHVTVP PW KANSKQPAFT IHVDEAEKEA QKKAESQKI EREDALAFNS
361 AISLPGPRKP LVPLDYPMDG SFESPHTMDM SIVLEDEKPV SVNEVPDYHE DIHTYLREME
421 VKCKPKVGYM KKQPDITNSM RAILVDWLVE VGEEYKLQNE TLHLAVNYID RFLSSMSVLR
481 GKLQLVG TAA MLLASKFEEI YPPEVAEFVY ITDDTYTKKQ VLRMEHLVLK VLTFDLAAPT
541 VNQFLTQYFL HQQPANCKVE SLAMFLGELS LIDADPYLKY LPSVIAGAAF HLALYTVTGG
601 SWPESLIRKT GYTLES LKPC LMDLHQTYLK APQHAQQSIR EK YKNSKYHG V SLLNPPETL
661 NL
  
```

### ***Recombinant cyclinA nucleotide sequence:***

```

1 atgtccccta tactaggtta ttgga a aatt aagggccttg tgcaaccac tcgacttctt
61 ttggaat atc ttgaagaaa atatgaagag c attt gatg agcgcgatga aggtgataaa
121 tggcgaaaca aaaagtttga attgggtttg gagtttccca atcttcctta ttatattgat
181 ggtgatgtta aattaacaca gtctatggcc atcatacgtt atatatgctga caagcacaac
241 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcggttttg
301 gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaagtt
361 gattttctta gcaagctacc tgaaatgctg aaaatggtcg aagatcgttt atgtcataaa
421 acatat ttaa atggtgatca tgtaaccat cctgacttca t gttgtatga cgctcttgat
481 gttgttttat acatggacc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa
541 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca
601 tggcctttgc agggctggca agccacgttt ggtgggtggcg accatcctcc aaaatcggat
661 ctggaagttc t gttccagg gcccgaattc atgttgggca actctgcgcc ggggcctgcg
721 acccgcgagg cgggctcggc gctgctagca ttgcagcaga cggcgctcca agaggaccag
781 gagaatatca acccggaaaa ggcagcgccc gtccaacaac cgcggaccgg ggccgcgctg
841 gcggtactga agtccgggaa cccgcggggt ctagcgcagc agcagaggcc gaagacgaga
901 cgggttgcac cccttaagga tcttcctgta aatgatgagc atgtcaccgt tcctccttgg
961 aaagcaaa ca gtaaacagcc tgcgttcacc attcatgtgg atgaagcaga aaaagaagct
1021 cagaagaagc cagctgaatc tcaaaaaata gagcgtgaag atgccctggc ttttaattca
1081 gccattagtt tacctggacc cagaaaacca ttggtccctc ttgattatcc aatggatggt
1141 agttttgagt caccacatac tatggacatg tcaattgtag tagaagatga aaagccagtg
1201 agtgttaatg aagtagcaga ctaccatgag gatattcaca cataccttag ggaaatggag
1261 gttaaatgta aacctaaagt gggttacatg aagaaacagc cagacatcac taacagtatg
1321 agagctatcc t cgtggactg gttagtgtgaa gtaggagaag aatataaact acagaatgag
1381 accctgcatt tggctgtgaa ctacattgat aggttcctgt cttccatgtc agtgctgaga
1441 gaaaaacttc agctgtggg cactgctgct atgctgttag cctcaaagtt tgaagaaata
1501 tacc cccag aagtagcaga gtttgtgtac attacagatg atacctacac caagaaaca
1561 gttctgagaa tggagcatct agttttgaaa gtccttactt ttgacttagc tgctccaaca
1621 gtaaatcagt ttcttacc ca atactttctg catcagcagc ctgcaaactg caaagttgaa
1681 agtttagcaa t gtttttggg agaattaagt ttgatagatg ctgaccata cctcaagat
  
```

## Certificate of Analysis

```
1741 ttgcatcag ttattgctgg agctgccttt catttagcac tctacacagt cacgggacaa
1801 agctggcctg aatcattaat acgaaagact ggatataccc tggaaagtct taagccttgt
1861 ctcattggacc ttcaccagac ctacctcaaa gcaccacagc atgcacaaca gtcaataaga
1921 gaaaagtaca aaaattcaaa gtatcatggt gtttctctcc tcaaccacc agagacacta
1981 aatctgtaa
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 **Eurofins Pharma Discovery Services UK Limited** is an independent member of Eurofins Discovery Services